Obese Patient During RARP: the Role of a Preemptive Ventilator Strategy to Contrast Pneumoperitoneum and Trendelenburg Position (OPERA)

June 5, 2013 updated by: PierPaolo Terragni, University of Turin, Italy

The Obese Patient in the Urologic Robotic Surgery: the Role of a Preemptive Ventilator Strategy and Partitioning to Contrast Pneumoperitoneum and Trendelenburg Position

Analysis of the specific elastance during general anesthesia in patients treated with RARP (robotic assisted radical prostatectomy), to evaluate the efficacy of the preemptive strategy, involving recruitment maneuver and setting of 10 cmH2O PEEP before induction of pneumoperitoneum and trendelenburg position.

Study Overview

Detailed Description

RARP (robotic assisted radical prostatectomy) requires the induction of pneumoperitoneum and the trendelenburg position, causing increase in the intra-abdominal pressure and cephalic shift of the diaphragm, with consequent airway closure and collapse of the dependent regions of the lung.

Obese subjects present an increased risk of respiratory complications, caused not only by the surgical procedure itself, but also by the respiratory mechanics changes associated with the body mass. In obese patients we can observe higher values of lung and chest wall elastance, with reduction in ventilation-perfusion ratio.

The partitioning between lung and chest wall elastance can improve ventilatory setting and mechanics parameters of ventilation.

In every patient we will place, after anesthesia induction, a catheter to get esophageal and gastric pressure that represent pleural and abdominal pressure.

Ventilation will be conducted with a tidal volume of 8-10 ml/kg (IBW) and a respiratory rate adequate to maintain a physiological level of Pa CO2.

The preemptive strategy involves recruitment maneuver and setting of 10 cmH2O PEEP before induction of pneumoperitoneum and trendelenburg position in the treatment group, while the current procedure provides it afterwards (control group).

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Turin, Italy, 10126
        • Recruiting
        • A.O.U San Luigi Gonzaga Hospital, Univesity of Turin
        • Contact:
        • Principal Investigator:
          • Pierpaolo Terragni, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • BMI >= 30
  • Robotic-assisted laparoscopic prostatectomy

Exclusion Criteria:

  • Chronic cardiac or pulmonary diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control
PEEP after pneumoperitoneum and trendelenburg
PEEP after pneumoperitoneum and trendelenburg
Experimental: Treatment
preemptive PEEP before pneumoperitoneum and trendelenburg
preemptive PEEP before pneumoperitoneum and trendelenburg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
evaluation of arterial oxygenation
Time Frame: at 6 hours (average duration of surgery procedure)
at 6 hours (average duration of surgery procedure)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
evaluation of specific static elastance of the lung
Time Frame: at 6 hours (average duration of surgery procedure)
Evaluation of the elastic properties of the lung (specific static elastance)
at 6 hours (average duration of surgery procedure)
evaluation of difference between arterial end-tidal partial pressure of carbon dioxide
Time Frame: at 6 hours (average duration of surgery procedure)
difference between arterial end-tidal partial pressure of carbon dioxide is an indicator of lung collapse and reopening after open-lung PEEP, which in turn reduce dead space
at 6 hours (average duration of surgery procedure)

Other Outcome Measures

Outcome Measure
Time Frame
variation of gas exchange in post operative period
Time Frame: at 1 week (average duration)
at 1 week (average duration)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pierpaolo Terragni, MD, University of Turin, Italy
  • Study Chair: Augusto Tempia, MD, University of Turin, Italy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2013

Primary Completion (Anticipated)

December 1, 2014

Study Completion (Anticipated)

December 1, 2014

Study Registration Dates

First Submitted

May 23, 2013

First Submitted That Met QC Criteria

May 29, 2013

First Posted (Estimate)

June 4, 2013

Study Record Updates

Last Update Posted (Estimate)

June 6, 2013

Last Update Submitted That Met QC Criteria

June 5, 2013

Last Verified

May 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obese Patients With Prostate Cancer Disease

Clinical Trials on control

3
Subscribe